Filing Flows › Halozyme Therapeutics (HALO) › Stock forecast & fair value
Halozyme Therapeutics (HALO) stock forecast and fair value
Halozyme Therapeutics (HALO) trades at $103.63. 9 analysts' median price target is $115.00 (+11%), from $79.00 to $130.00. Across 26 valuation methods the middle fair value is $101.13 (-2%); the DCF says $190.45.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | $66.11 | $225.12 | $1,029.78 | +117% |
| DCF — Monte Carlo 10th–90th percentile | $108.04 | $190.45 | $289.73 | +84% |
| P/E vs peers | $72.82 | $101.13 | $277.64 | -2% |
| P/E vs peers, weighted | $82.64 | $104.67 | $176.72 | +1% |
| EV/EBITDA vs peers | $85.24 | $87.25 | $269.21 | -16% |
| EV/EBITDA vs peers, weighted | $85.59 | $87.23 | $164.88 | -16% |
| EV/Sales vs peers | $73.34 | $99.72 | $222.14 | -4% |
| EV/Sales vs peers, weighted | $51.88 | $78.92 | $98.23 | -24% |
| EV/Sales vs peers, growth & margin adjusted | $34.00 | $58.63 | $97.36 | -43% |
| Residual income | $262.20 | $277.49 | $293.90 | +168% |
Halozyme Therapeutics' latest quarter
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for HALO stock?
The median of 9 analysts' 12-month targets is $115.00, +11% from $103.63; the range is $79.00 to $130.00. The average rating is buy.
What is Halozyme Therapeutics' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $10.21 and $277.49, with a middle value of $101.13 against a price of $103.63. Each method's assumptions are on the page.
Does Halozyme Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is HALO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.